

# Cornelia Barbara Landersdorfer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7625797/publications.pdf>

Version: 2024-02-01

116  
papers

4,368  
citations

117453

34  
h-index

128067

60  
g-index

122  
all docs

122  
docs citations

122  
times ranked

4702  
citing authors

#	ARTICLE	IF	CITATIONS
1	Differences in Fosfomycin Resistance Mechanisms between <i>Pseudomonas aeruginosa</i> and <i>Enterobacterales</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0144621.	1.4	5
2	Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable <i>Pseudomonas aeruginosa</i> via a Dynamic Biofilm Model and Mechanism-Based Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, aac0220321.	1.4	4
3	Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model. <i>Antibiotics</i> , 2022, 11, 101.	1.5	4
4	Population Pharmacokinetics of Moxifloxacin in Children. <i>Paediatric Drugs</i> , 2022, 24, 163-173.	1.3	1
5	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	1.3	1
6	Research priorities towards precision antibiotic therapy to improve patient care. <i>Lancet Microbe</i> , The, 2022, 3, e795-e802.	3.4	17
7	Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1000-1020.	2.3	10
8	Key Challenges in Providing Effective Antibiotic Therapy for Critically Ill Patients with Bacterial Sepsis and Septic Shock. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 892-904.	2.3	20
9	Evaluation of Meropenem-Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1104-1115.	2.3	16
10	How important are MIC determination methods when targeting vancomycin levels in patients with <i>Staphylococcus aureus</i> infections?. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1641-1643.	1.3	1
11	Population Pharmacokinetics and Outcomes of Critically Ill Pediatric Patients Treated with Intravenous Colistin at Higher Than Recommended Doses. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	7
12	Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106368.	1.1	17
13	Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable <i>Pseudomonas aeruginosa</i> isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 26, 55-63.	0.9	7
14	Limitations of Antibiotic MIC-Based PK-PD Metrics: Looking Back to Move Forward. <i>Frontiers in Pharmacology</i> , 2021, 12, 770518.	1.6	31
15	A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant <i>Klebsiella pneumoniae</i> infections. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105833.	1.1	81
16	Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis. <i>Pharmaceutical Research</i> , 2020, 37, 3.	1.7	23
17	Mortality, clinical and microbiological response following antibiotic therapy among patients with carbapenem-resistant <i>Klebsiella pneumoniae</i> infections (a meta-analysis dataset). <i>Data in Brief</i> , 2020, 28, 104907.	0.5	2
18	Performance of Four Fosfomycin Susceptibility Testing Methods against an International Collection of Clinical <i>Pseudomonas aeruginosa</i> Isolates. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	12

#	ARTICLE	IF	CITATIONS
19	Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable <i>Pseudomonas aeruginosa</i> in a Dynamic Biofilm Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	7
20	Physiologically Based Population Pharmacokinetic Modeling Approach for Ciprofloxacin in Bone of Patients Undergoing Orthopedic Surgery. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 444-454.	2.5	11
21	Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1621-1631.	1.4	342
22	Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>Clinical Microbiology and Infection</i> , 2020, 26, 1207-1213.	2.8	28
23	Nanosilver Mitigates Biofilm Formation via FapC Amyloidosis Inhibition. <i>Small</i> , 2020, 16, e1906674.	5.2	26
24	Four Decades of $\beta$ -Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 143-156.	1.6	15
25	Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable <i>Pseudomonas aeruginosa</i> at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	11
26	Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics. <i>Pharmaceutics</i> , 2019, 11, 323.	2.0	4
27	Optimization of dosing regimens of intravenous colistin in patients with cystic fibrosis: What data are required?. <i>Pediatric Pulmonology</i> , 2019, 54, 1497-1498.	1.0	2
28	Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable <i>Pseudomonas Aeruginosa</i> Strains via Mechanism-Based Modelling. <i>Pharmaceutics</i> , 2019, 11, 470.	2.0	4
29	Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding. <i>Pharmaceutics</i> , 2019, 11, 286.	2.0	10
30	Population Pharmacokinetics of Intravenous Colistin in Pediatric Patients: Implications for the Selection of Dosage Regimens. <i>Clinical Infectious Diseases</i> , 2019, 69, 1962-1968.	2.9	19
31	Characterization of Hypermutator <i>Pseudomonas aeruginosa</i> Isolates from Patients with Cystic Fibrosis in Australia. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	30
32	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	1.4	21
33	An optimised Cu(0)-RDRP approach for the synthesis of lipidated oligomeric vinyl azlactone: toward a versatile antimicrobial materials screening platform. <i>Journal of Materials Chemistry B</i> , 2019, 7, 6796-6809.	2.9	11
34	Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against <i>Pseudomonas aeruginosa</i> for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	21
35	Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against <i>Pseudomonas aeruginosa</i> using a dynamic in vitro model. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1570-1578.	1.3	21
36	Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable <i>Pseudomonas aeruginosa</i> via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	31

#	ARTICLE	IF	CITATIONS
37	Combating Carbapenem-Resistant <i>Acinetobacter baumannii</i> by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	10
38	Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD). <i>Drug Delivery and Translational Research</i> , 2018, 8, 729-739.	3.0	11
39	In reply. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 253-253.	0.8	0
40	Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against <i>Pseudomonas aeruginosa</i> and <i>Escherichia coli</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 69-76.	0.8	4
41	Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against <i>Klebsiella pneumoniae</i> in mouse thigh and lung infection models. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 462-468.	1.3	86
42	The pharmacokinetics of intranasal droperidol in volunteers characterised via population modelling. <i>SAGE Open Medicine</i> , 2018, 6, 205031211881328.	0.7	2
43	Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	67
44	Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	3
45	First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 123, 416-428.	1.9	6
46	Meropenem Combined with Ciprofloxacin Combats Hypermutable <i>Pseudomonas aeruginosa</i> from Respiratory Infections of Cystic Fibrosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	26
47	Prolonged and continuous antibacterial and anti-biofilm activities of thin films embedded with gentamicin-loaded mesoporous silica nanoparticles. <i>Applied Nanoscience (Switzerland)</i> , 2018, 8, 1471-1482.	1.6	13
48	Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics. <i>Clinical Pharmacokinetics</i> , 2017, 56, 77-90.	1.6	36
49	Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	34
50	Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	27
51	Pharmacokinetic modelling of modified acetylcysteine infusion regimens used in the treatment of paracetamol poisoning. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1103-1110.	0.8	10
52	Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 107, 32-44.	1.9	4
53	Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in a Murine Thigh Infection Model by Using Humanized Dosing Schemes. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	18
54	Aminoglycoside Concentrations Required for Synergy with Carbapenems against <i>Pseudomonas aeruginosa</i> Determined via Mechanistic Studies and Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	31

#	ARTICLE	IF	CITATIONS
55	Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical <i>Pseudomonas aeruginosa</i> Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	27
56	High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 153-165.	1.3	36
57	Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3913-3920.	1.4	43
58	Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of <i>Pseudomonas aeruginosa</i> , but do not suppress the emergence of fosfomycin resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2218-2229.	1.3	32
59	Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3157-3167.	1.3	26
60	Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 719-724.	1.1	14
61	Polymyxin B in combination with doripenem against heteroresistant <i>Acinetobacter baumannii</i> : pharmacodynamics of new dosing strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3148-3156.	1.3	36
62	Effect of different renal function on antibacterial effects of piperacillin against <i>Pseudomonas aeruginosa</i> evaluated via the hollow-fibre infection model and mechanism-based modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2509-2520.	1.3	38
63	Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab <sup>2</sup> Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity. <i>Molecular Pharmaceutics</i> , 2016, 13, 1229-1241.	2.3	25
64	External manipulation of nanostructure in photoresponsive lipid depot matrix to control and predict drug release in vivo. <i>Journal of Controlled Release</i> , 2016, 228, 67-73.	4.8	29
65	Colistin: How should It Be Dosed for the Critically Ill?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 126-135.	0.8	55
66	PEGylated Interferon Displays Differences in Plasma Clearance and Bioavailability Between Male and Female Mice and Between Female Immunocompetent C57Bl/6j and Athymic Nude Mice. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 1848-1855.	1.6	6
67	Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. <i>Infectious Diseases and Therapy</i> , 2015, 4, 391-415.	1.8	45
68	Stability and controlled antibiotic release from thin films embedded with antibiotic loaded mesoporous silica nanoparticles. <i>RSC Advances</i> , 2015, 5, 107839-107846.	1.7	11
69	Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 818-826.	1.3	20
70	Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use. <i>Pharmacotherapy</i> , 2015, 35, 34-42.	1.2	52
71	Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2286-2298.	1.4	52
72	Colistin and doripenem combinations against <i>Pseudomonas aeruginosa</i> : profiling the time course of synergistic killing and prevention of resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1434-1442.	1.3	60

#	ARTICLE	IF	CITATIONS
73	Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1804-11.	1.3	21
74	Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans. <i>AAPS Journal</i> , 2015, 17, 1210-1223.	2.2	20
75	Population Pharmacokinetic/Pharmacodynamic Modelling of Dipeptidyl Peptidase IV Inhibitors. <i>Clinical Pharmacokinetics</i> , 2015, 54, 673-675.	1.6	0
76	Two Mechanisms of Killing of <i>Pseudomonas aeruginosa</i> by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2315-2327.	1.4	76
77	Evaluation of enrofloxacin use in koalas ( <i>Peromyscus cinereus</i> ) via population pharmacokinetics and Monte Carlo simulation. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2014, 37, 301-311.	0.6	14
78	Quantitative Determination of Absorption and First-Pass Metabolism of Apicidin, a Potent Histone Deacetylase Inhibitor. <i>Drug Metabolism and Disposition</i> , 2014, 42, 974-982.	1.7	9
79	Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in End-Stage Renal Disease Patients Receiving Continuous Ambulatory Peritoneal Dialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 440-446.	1.4	30
80	Reply to Pai. <i>Clinical Infectious Diseases</i> , 2013, 57, 1786-1786.	2.9	2
81	PK/PD models in antibacterial development. <i>Current Opinion in Microbiology</i> , 2013, 16, 573-579.	2.3	61
82	Combination therapy for carbapenem-resistant Gram-negative bacteria. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 1333-1353.	2.0	112
83	Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens. <i>Clinical Infectious Diseases</i> , 2013, 57, 524-531.	2.9	351
84	Study Reanalysis Using a Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Pramlintide in Subjects with Type 1 Diabetes. <i>AAPS Journal</i> , 2013, 15, 15-29.	2.2	10
85	Pharmacokinetic Modeling and Simulation of Biweekly Subcutaneous Immunoglobulin Dosing in Primary Immunodeficiency. <i>Postgraduate Medicine</i> , 2013, 125, 53-61.	0.9	31
86	Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 674-677.	1.3	63
87	A Pharmacometric Approach to Investigate the Impact of Methylxanthine Abstinence and Caffeine Consumption on CYP1A2 Activity. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1957-1966.	1.7	8
88	Quantifying Subpopulation Synergy for Antibiotic Combinations via Mechanism-Based Modeling and a Sequential Dosing Design. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2343-2351.	1.4	68
89	Old antibiotics for emerging multidrug-resistant bacteria. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 626-633.	1.3	103
90	Population Pharmacokinetics of Piperacillin at Two Dose Levels: Influence of Nonlinear Pharmacokinetics on the Pharmacodynamic Profile. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5715-5723.	1.4	30



#	ARTICLE	IF	CITATIONS
91	Pharmacokinetics and pharmacodynamics of $\epsilon$ -old $\epsilon$ ™ polymyxins: what is new?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 74, 213-223.	0.8	144
92	Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 391-401.	1.1	29
93	Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 373-390.	1.1	19
94	Development of a New Pre- and Post-Processing Tool (SADAPT-TRAN) for Nonlinear Mixed-Effects Modeling in S-ADAPT. <i>AAPS Journal</i> , 2011, 13, 201-211.	2.2	111
95	Performance and Robustness of the Monte Carlo Importance Sampling Algorithm Using Parallelized S-ADAPT for Basic and Complex Mechanistic Models. <i>AAPS Journal</i> , 2011, 13, 212-226.	2.2	83
96	Relevance of Pharmacokinetic and Pharmacodynamic Modeling to Clinical Care of Critically Ill Patients. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 2044-2061.	0.9	47
97	Population Pharmacokinetics and Penetration into Prostatic, Seminal, and Vaginal Fluid for Ciprofloxacin, Levofloxacin, and Their Combination. <i>Chemotherapy</i> , 2011, 57, 402-416.	0.8	21
98	Comparable Population Pharmacokinetics and Pharmacodynamic Breakpoints of Cefpirome in Cystic Fibrosis Patients and Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2927-2936.	1.4	10
99	Pharmacodynamic Modeling of Anti-Cancer Activity of Tetraiodothyroacetic Acid in a Perfused Cell Culture System. <i>PLoS Computational Biology</i> , 2011, 7, e1001073.	1.5	52
100	First-Dose Pharmacokinetics of Lithium Carbonate in Children and Adolescents. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 404-410.	0.7	32
101	Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 167-178.	1.1	41
102	Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1275-1282.	1.4	48
103	Pharmacokinetic/Pharmacodynamic Modeling of Glucose Clamp Effects of Inhaled and Subcutaneous Insulin in Healthy Volunteers and Diabetic Patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 418-429.	1.1	18
104	Bone Penetration of Amoxicillin and Clavulanic Acid Evaluated by Population Pharmacokinetics and Monte Carlo Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2569-2578.	1.4	30
105	New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3462-3471.	1.4	19
106	Penetration of Moxifloxacin into Bone Evaluated by Monte Carlo Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2074-2081.	1.4	32
107	Competitive Inhibition of Renal Tubular Secretion of Gemifloxacin by Probenecid. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3902-3907.	1.4	19
108	Mechanism-Based Modeling of Nutritional and Leptin Influences on Growth in Normal and Type 2 Diabetic Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 328, 644-651.	1.3	10

#	ARTICLE	IF	CITATIONS
109	The time course of drug effects. <i>Pharmaceutical Statistics</i> , 2009, 8, 176-185.	0.7	15
110	Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 65, 130-141.	0.8	17
111	Penetration of Antibacterials into Bone. <i>Clinical Pharmacokinetics</i> , 2009, 48, 89-124.	1.6	252
112	Inhibition of flucloxacillin tubular renal secretion by piperacillin. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 648-659.	1.1	34
113	Pharmacokinetic/Pharmacodynamic Modelling in??Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2008, 47, 417-448.	1.6	83
114	Population Pharmacokinetics at Two Dose Levels and Pharmacodynamic Profiling of Flucloxacillin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3290-3297.	1.4	63
115	Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1881-1889.	1.4	87
116	Acrylamide: Increased Concentrations in Homemade Food and First Evidence of Its Variable Absorption from Food, Variable Metabolism and Placental and Breast Milk Transfer in Humans. <i>Chemotherapy</i> , 2002, 48, 267-274.	0.8	158